TRIDERLIN

This brand name is authorized in Nigeria.

Active ingredients

The drug TRIDERLIN contains a combination of these active pharmaceutical ingredients (APIs):

1	Neomycin UNII 057Y626693 - NEOMYCIN SULFATE
	Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.
	Read more about Neomycin
2	Bacitracin UNII 89Y4M234ES - BACITRACIN ZINC
	Read more about Bacitracin
3	Polymyxin B UNII 19371312D4 - POLYMYXIN B SULFATE
	Polymixin B is bactericidal against a wide range of gram negative bacilli. It exerts a bactericidal effect by binding to acid phospholipids in the cell wall and membranes of the bacterium, thereby rendering ineffective the osmotic barrier normally provided by the cell membrane.
	Read more about Polymyxin B

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100750	Ointment	Triderlin Ointment OINTMENT 3.5 mg/g; 400 units/g; 10,000 units/g 1 X 30G	1 NF-PP-348260 Triderlin Ointment Bacitracin Zinc 500IU, Polymyxin B Sulfate 10000IU, Neomycin 3.5mg, Pramoxine hydrochloride 10mg Bacitracin Zinc 500IU, Polymyxin B Sulfate 10000IU, Neomycin 3.5mg, Pramoxine hydrochloride 10mg (Excipients: Liquid Paraffin, White soft paraffin) A4-100750 Drugs Imported Products 1x30g POM 1 8/9/2023 AKSO PHARMACEUTICAL NIGERIA LIMITED, ODUSAMI STREET OFF WEMPCO ROAD OGBA IKEJA LAGOS 8180218332 506798052@qq.com FRONT PHARMACEUTICAL PLC., ECONOMIC AND TECHNICAL DEVELOPMENT ZONE, XUANCHENG, ANHUI PROVINCE, CHINA, China	28/02/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07AA51	Neomycin, combinations	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07A Intestinal antiinfectives → A07AA Antibiotics
Discover more medicines within A07AA51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100750